Acelrx Pharmaceuticals Stock News

Acelrx Pharmaceuticals Inc (ACRX) shares closed today at 0.3% above its 52 week low of $0.65, giving the company a market cap of $80M. The stock is currently down 45.4% year-to-date, down 56.0% over the past 12 months, and down 77.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 43.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 35.4% The company's stock price performance over the past 12 months lags the peer average by 107.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Jill

AIkido Pharma Inc. (AIKI) with the stream of 0.50% also noticed, India AcelRx Pharmaceuticals, Inc. (ACRX) encountered a rapid change of -2.70% in the last hour of Monday’s trading session. … The post Remarkable Stock Buzz: AIkido Pharma Inc. (NASDAQ:AIKI), AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) appeared first on Stocks Equity .

AcelRx Pharmaceuticals, Inc. (ACRX) with the stream of 6.00% also noticed, India Cocrystal Pharma, Inc. (COCP) encountered a rapid change of -1.69% in the last hour of Fridays trading session. The post Is It Overvalued? Look at the P/S Ratio: AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), Cocrystal Pharma, Inc. (NASDAQ:COCP) appeared first on Stocks Equity .

Geode Capital Management LLC reduced its stake in shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) by 37.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,050,806 shares of the specialty pharmaceutical companys stock after selling 620,752 shares during the period. Geode Capital Management []

Zacks Investment Research cut shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a hold rating to a sell rating in a research report report published on Thursday morning, Zacks.com reports. According to Zacks, AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product []

AcelRx Pharmaceuticals (NASDAQ:ACRX) posted its quarterly earnings results on Sunday. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter, hitting the Zacks consensus estimate of ($0.07), MarketWatch Earnings reports. During the same period in the previous year, the company earned ($0.10) EPS. ACRX stock opened at $0.75 on Tuesday. The firm has []

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) has agreed to acquire privately-held Lowell Therapeutics Inc for approximately $32.5 million. The deal consideration includes approximately $26 million of contingent consideration payable in cash or stock. Lowell is developing Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney Full story available on Benzinga.com

(RTTNews) - AcelRx Pharmaceuticals, Inc. (ACRX) reported a third-quarter loss per share of $0.07 compared to a loss of $0.10, prior year. Analysts polled by Thomson Reuters expected the company to report a loss per share of $0.07, for the quarter. Analysts'' estimates typically exclude special items. Net loss was $8.4 million compared to a loss

HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of a

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q3 2021 Results - Earnings Call Transcript

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to acquire privately-held Lowell Therapeutics Inc for approximately $32.5 million. The deal consideration includes approximately $26 million o